Company: CYTK
Filing Date: 2025-05-16
Form Type: 8-K
Source: 0000950170-25-072965
Chunk: 1

Company: CYTOKINETICS INC
Filing Date: 2025-05-16
Form: 8-K
Item: Item 5.07
Chunk 1
---
 Incentive Plan to: (i) increase the number of authorized shares reserved for issuance under the Amended and Restated 2004 Equity Incentive Plan by an additional 5,000,000 shares of common stock and (ii) provide for limitations on the maximum grant value that non-executive directors may receive under such plan of $1,000,000 for annual grants to continuing directors and $1,250,000 for the initial grant to new directors. The votes were as follows:

  For                      Against                     Abstain                   Broker Non-Vote                 
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────
           97,782,771                   3,668,240                   168,029                           8,867,164  

Proposal 3: Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock available for issuance by the Company from 163,000,000 to 326,000,000 shares of common stock.

The stockholders approved the amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock available for issuance by the Company from 163,000,000 to 326,000,000 shares of common stock. The votes were as follows:

  For                       Against                     Abstain                   Broker Non-Vote           
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────
           107,322,080                   3,009,572                   154,552                           -0-  

Proposal 4: Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025

The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The votes were as follows:

  For                       Against                  Abstain                   Broker Non-Vote           
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────
           110,254,216                   77,441                   154,547                           -0-  

Proposal 5: Advisory Vote on Executive Compensation

The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company’s Proxy Statement for the 2025 Annual Meeting of Shareholders.